DPP4 and diabetes mellitus: The second trend can be linked to significant development and interest in peroxisome proliferator-activated receptor and glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase IV and sodium glucose co-transporter inhibitors, all of which address carbohydrate metabolism and diabetes.